ANTI-CD40 ANTIBODY-BINDING MODULATES HUMAN MULTIPLE-MYELOMA CLONOGENICITY IN-VITRO

被引：0
|
作者：
TONG, AW
SU, D
MUES, G
SOLANO, M
STONE, MJ
机构：
[1] BAYLOR UNIV,BAYLOR SAMMONS CANC CTR,MED CTR,DALLAS,TX
[2] BAYLOR RES INST,M CROWLEY LAB,DALLAS,TX
来源：
BLOOD | 1994年 / 84卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A170 / A170
页数：1
相关论文
共 50 条
  • [21] Identification of a strongly activating human Anti-CD40 antibody that suppresses HIV type 1 infection
    Ellmark, Peter
    Andersson, Henrik
    Abayneh, Sisay
    Fenyo, Eva Maria
    Borrebaeck, Carl A. K.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 (03) : 367 - 373
  • [22] Cross-linking of CD40 using anti-CD40 antibody, 5C11, has different effects on XG2 multiple myeloma cells
    Qi, CH
    Zheng, L
    Zhou, X
    Tao, Y
    Ge, Y
    Zhuang, YM
    Xu, Y
    Yu, GH
    Zhang, XG
    IMMUNOLOGY LETTERS, 2004, 93 (2-3) : 151 - 158
  • [23] In vitro testing of an anti-CD40 monoclonal antibody, clone 2C10, in primates and pigs
    Lee, Whayoung
    Satyananda, Vikas
    Iwase, Hayato
    Tanaka, Takayuki
    Miyagawa, Yuko
    Long, Cassandra
    Ayares, David
    Cooper, David K. C.
    Hara, Hidetaka
    TRANSPLANT IMMUNOLOGY, 2015, 33 (03) : 185 - 191
  • [24] RETRACTION: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications (Retraction of Vol 64, Pg 2846, 2004)
    Tai, Yu-Tzu
    Catley, Laurence P.
    Mitsiades, Constantine S.
    Burger, Renate
    Podar, Klaus
    Shringpaure, Reshma
    Hideshima, Teru
    Chauhan, Dharminder
    Hamasaki, Makoto
    Ishitsuka, Kenji
    Richardson, Paul
    Treon, Steven P.
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    CANCER RESEARCH, 2024, 84 (06) : 936 - 936
  • [25] VALIDATION OF PATHOGENIC ROLE OF ANTI-CD40 ANTIBODY IN PODOCYTES IN VITRO AND PROTEINURIA CAUSING KIDNEY INJURY IN MICE
    Sigdel, T.
    Sarwal, M.
    Wei, C.
    Reiser, J.
    PEDIATRIC TRANSPLANTATION, 2015, 19 : 74 - 74
  • [26] Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rheumatoid Arthritis (RA)
    Visvanathan, Sudha
    Ramanujam, Meera
    Schoelch, Corinna
    Baum, Patrick
    Vinisko, Richard
    Thiedmann, Ralf
    Mueller-Ladner, Ulf
    Daniluk, Stefan
    Ptaszynski, Rafal
    Padula, Steven
    Fine, Jay S.
    Steffgen, Juergen
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [27] Preliminary phase 1 evaluations of 2 anti-CD40 monoclonal antibodies in patients with relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 342 - 344
  • [28] In vitro activity of a novel fully human anti-CD40 antibody CHIR-12.12 in chronic lymphocytic leukemia:: Blockade of CD40 activation and induction of ADCC.
    Tong, X
    Georgakis, GV
    Li, L
    Susan, O
    Anas, Y
    Mohammad, L
    BLOOD, 2004, 104 (11) : 686A - 686A
  • [29] Cross-linking of CD40 using Anti-CD40 antibody, 5C11, had different effects on XG2 multiple myeloma cells.
    Qi, CJ
    Shi, HZ
    Shi, Q
    Gu, T
    Zhuang, YM
    Xi, H
    Zhang, ZX
    BLOOD, 2002, 100 (11) : 368B - 368B
  • [30] Extracellular matrix-binding anti-CD40 agonistic antibody reduces systemic damages and increases anti-tumor efficacy
    Ishihara, Jun
    Ishihara, Ako
    CANCER SCIENCE, 2018, 109 : 1055 - 1055
12345